Fecal Calprotectin Level in Children with Cystic Fibrosis

Keywords

Calprotectin
Children
Cystic fibrosis
Mucosal inflammation
Pancreatic insufficiency

Categories

How to Cite

Rafeey, M., Jafari-Rouhi, A. H. ., Hejrati, S. .,  yasari, S., Hosseinpour Sarmadi, M., & Farhadi, E. . (2022). Fecal Calprotectin Level in Children with Cystic Fibrosis. Iranian Red Crescent Medical Journal, 24(11). https://doi.org/10.32592/ircmj.2022.24.11.1531

Abstract

Background: Early diagnosis of cystic fibrosis (CF) and hence the initiation of symptomatic and prophylactic treatment can help improve the outcomes of CF patients. Fecal calprotectin (FC) is a marker of inflammation in the intestinal tract that is elevated in several gastrointestinal inflammatory diseases, but little is known about its value in CF.

Objectives: This study, therefore, aimed to survey the associations of FC among CF patients and its correlation with the clinical manifestations of CF.

Methods: This descriptive cross-sectional study was performed on 52 children with CF visiting the Children’s Hospital of Tabriz, Iran, during 2018-2019, selected through the census sampling method. The calprotectin values of <50 μg/g were considered normal.

Results: There was no clinically relevant association among FC levels concerning pancreatic insufficiency, diabetes, and airway colonization with Pseudomonas. In a comparison of the number of exacerbations and Forced Expiratory Volume in the first second (FEV1), the levels of electrolytes showed no significant difference between patients with normal calprotectin and elevated FC. The results of the performed analysis indicated no significant difference between the low-fecal elastase and the FC levels in patients with CF (P=0.53).

Conclusion: Demographic and clinical parameters, such as age, gender, FEV1, or Body Mass Index, had no clinically significant relationship with FC. However, serial and longitudinal calprotectin levels should also be checked, which may have clinical relevance during symptomatic episodes.

https://doi.org/10.32592/ircmj.2022.24.11.1531

References

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. [PubMed: 31570318].

De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109(5):893-9. doi: 10.1111/apa.15155. [PubMed: 31899933].

Ortiz-Muñoz G, Michelle AY, Lefrançais E, Mallavia B,

Valet C, Tian JJ, et al. Cystic fibrosis transmembrane

conductance regulator dysfunction in platelets drives lung hyperinflammation. J Clin Invest. 2020;130(4):2041-53. doi: 10.1172/JCI129635. [PubMed: 31961827].

Bryon M. Breaking the diagnosis of cystic fibrosis to parents: a process not a one-off event. Paediatr Respir Rev. 2020;35:103-5. doi: 10.1016/j.prrv.2020.04.006. [PubMed: 32409170].

Fatima T, Ajjarapu S, Shankar VK, Rangappa S, Shivakumar HN, Biswas SK, et al. Topical pilocarpine formulation for diagnosis of cystic fibrosis. J Pharm Sci. 2020;109(5):1747-51. doi: 10.1016/j.xphs.2020.01.030. [PubMed: 32035925].

Kopi TA, Shahrokh S, Mirzaei S, Aghdaei HA, Kadijani AA. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019;12(3):183-9. [PubMed: 31528300].

Talebi S, Day AS, Rezaiyan MK, Ranjbar G, Zarei M, Safarian M, et al. Fecal calprotectin and phenotype severity in patients with cystic fibrosis: a systematic review and meta-analysis. Pediatr Gastroenterol Hepatol Nutr. 2022;25(1):1-12.‏ doi: 10.5223/pghn.2022.25.1.1. [PubMed: 35087728].

Shabestari MS, Rafeey M, Shoaran M, Shirvani S. Association between fecal calprotectin concentration and mesenteric lymphadenopathy in children. Crescent J Med Biol Sci. 2020;7(2):238-42.

Mosavi A, Mosavi H, Zare S, Gadarjani R. Evaluation of fecal calprotectin in the assessment of patients with inflammatory bowel disease in the Shahid Mohammadi Hospital in Hormozgan in 2013-2014. J Rafsanjan Univ Med Sci. 2017;15(12):1107-18.

Xiang BJ, Jiang M, Sun MJ, Dai C. Optimal range of

fecal calprotectin for predicting mucosal healing in

patients with inflammatory Bowel Disease: a systematic review and meta-analysis. Visc Med. 2021;37(5):338-48. doi: 10.1159/000514196. [PubMed: 34722717].

D'Amico F, Bonovas S, Danese S, Peyrin‐Biroulet L. faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(7):689-98. doi: 10.1111/apt.15662. [PubMed: 32048751].

Xiang B, Dong Z, Dai C. The diagnostic and predictive value of Fecal calprotectin and capsule endoscopy for small-bowel Crohn's disease: A systematic review and meta-analysis.

Rev Esp Enferm Dig. 2021;113(3):193-201. doi: 10.17235/reed.2020.6996/2020. [PubMed: 33207888].

Kapel N, Campeotto F, Kalach N, Baldassare M, Butel M-J, Dupont C. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010;51(5):542-7. doi: 10.1097/MPG.0b013e3181e2ad72. [PubMed: 20818270].

Więcek S, Woś H, Kordys-Darmolińska B, Sankiewicz-Szkółka M, Grzybowska-Chlebowczyk U. The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis. Gastroenterology Rev. 2017;12(1):38–43. doi: 10.5114/pg.2016.58897.

Ellemunter H, Engelhardt A, Schüller K, Steinkamp G. Fecal calprotectin in cystic fibrosis and its relation to disease parameters: a longitudinal analysis for 12 years

. J Pediatr Gastroenterol Nutr. 2017;65(4):438-442. doi: 10.1097/MPG.0000000000001544. [PubMed: 28207476].

Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, et al. Calprotectin in cystic fibrosis. BMC Pediatr. 2014;14(1):1-7. doi: 10.1186/1471-2431-14-133. [PubMed: 24885444].

Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee J, et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60(4):521-6. doi: 10.1097/MPG.0000000000000683. [PubMed: 25539196].